Essential Partners
NBIX icon

Essential Partners’s Neurocrine Biosciences NBIX Stock Holding History

Essential Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$164K Sell
1,159
-901
-44% -$145K 0.08% 291
2026
Q2 		$347K Sell
2,060
-3,409
-62% -$506K 0.16% 130
2026
Q1 		$720K Sell
5,469
-636
-10% -$84.4K 0.24% 106
2025
Q4 		$866K Buy
6,105
+588
+11% +$85.2K 0.27% 101
2025
Q3 		$774K Buy
5,517
+2,937
+114% +$398K 0.26% 106
2025
Q2 		$324K Buy
+2,580
New +$296K 0.13% 220

Other funds holding NBIX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
PKO BP Bankowy Universal Pension Society
PKO BP Bankowy Universal Pension Society Warsaw, Poland $340M AUM 228.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Fjarde Ap-fonden
Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Essential Partners's NBIX Position: Q3 2026 in Review

Essential Partners reduced its Neurocrine Biosciences (NBIX) stake by 44% in Q3 2026, selling an estimated $145K and leaving 1,159 shares worth $164K. The position accounts for 0.08% of the portfolio, ranked #291.

Essential Partners first reported a position in NBIX in Q2 2025 and has held it in 6 quarters since. The position peaked at $866K in Q4 2025. 132 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Essential Partners held 1,159 shares of Neurocrine Biosciences worth $164K as of Q3 2026.
  • Essential Partners sold 901 Neurocrine Biosciences shares in Q3 2026, an estimated $145K.
  • Neurocrine Biosciences made up 0.08% of Essential Partners's portfolio in Q3 2026, its #291 holding.
  • Essential Partners first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's Neurocrine Biosciences position peaked at $866K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.